Incannex Healthcare Limited (ASX:IHL) – Incannex Announces Positive Results From Phase 2 Clinical Trial

Incannex (NASDAQ: IXHL) (ASX: IHL) announced positive results from the phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea.

IHL42x trial has significantly exceeded the company’s expectations. It has shown substantial clinical benefit to people with obstructive sleep apnoea at the lowest dose given. This not only means people can get the full benefit with a reduced risk of side effects, but also, during the low dose treatment period every subject was substantially below the legal driving limits for THC in their blood the morning after dosing, thus removing a significant hurdle for IHL-42X’s widespread use.

Highlights of the announcement (please click on link) are:

• IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed
• Low dose IHL-42X exhibited superior safety and efficacy metrics to mid and high doses
• Low dose IHL-42X reduced AHI by an average of 50.7% compared to baseline with 25% of participants experiencing a reduction in the apnoea hypopnea index of greater that 80%
• Oxygen desaturation index was reduced by 59.7% relative to baseline while taking low dose IHL-42X, improving sleep quality and reducing cardiovascular stress
• In low dose IHL-42X samples, THC concentrations in blood were well below the limits for impaired driving the morning after dose administration
• IHL-42X was well tolerated – low dose IHL-42X was observed to have a lower number of total treatment emergent adverse events than placebo
• Low dose IHL-42X reduced AHI substantially more effectively than is reported for the component active pharmaceutical ingredients, dronabinol and acetazolamide, as unregistered monotherapies.

Incannex also released a presentation in conjunction with the above announcement which can be found by clicking on the link below.

IHL-42X for treatment of obstructive sleep apnoea


Contact Us